高级搜索
128例初治鼻咽癌调强适形放疗临床分析[J]. 肿瘤防治研究, 2010, 37(05): 570-574. DOI: 10.3971/j.issn.1000-8578.2010.05.022
引用本文: 128例初治鼻咽癌调强适形放疗临床分析[J]. 肿瘤防治研究, 2010, 37(05): 570-574. DOI: 10.3971/j.issn.1000-8578.2010.05.022
Clinical Observation of 128 Nasopharyngeal Carcinoma Patients for Intensity Modulated Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2010, 37(05): 570-574. DOI: 10.3971/j.issn.1000-8578.2010.05.022
Citation: Clinical Observation of 128 Nasopharyngeal Carcinoma Patients for Intensity Modulated Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2010, 37(05): 570-574. DOI: 10.3971/j.issn.1000-8578.2010.05.022

128例初治鼻咽癌调强适形放疗临床分析

Clinical Observation of 128 Nasopharyngeal Carcinoma Patients for Intensity Modulated Radiotherapy

  • 摘要: 目的 分析调强适形放疗(intensity modulated radiation therapy,IMRT) 治疗初治鼻咽癌的临床疗效。 方法 鼻咽癌IMRT 初治患者128例,按1992年福州分期标准,Ⅰ期2例,Ⅱ期19例,Ⅲ期58例,Ⅳa期49例。鼻咽大体肿瘤体积(GTVnx)处方剂量为(70~74)Gy分30次,颈部淋巴结(GTVnd)处方剂量为(68~70)Gy分30次,临床靶体积1(CTV1)(60~64)Gy分30次,临床靶体积2(CTV2)(50~54)Gy分30次。采用Kaplan-Meier法进行生存分析和局部控制率计算,Log-rank检验组间差异。 结果 中位随访时间12月(6~24月),1、2 年总生存率分别为100%、96.9%,1、2 年无远处转移生存率分别为92.2%、88.3%,1、2 年局部控制率分别为96.1%和93.8%。N分期是影响有无远处转移生存率的最重要预后因素( P =0.04)。最严重的急性不良反应是放射性黏膜炎,Ⅰ~Ⅳ级分别为38.8%、48.4%、7.8%、0。晚期不良反应主要表现为口干,Ⅰ级67.2%, Ⅱ级19.5%。 结论 鼻咽癌IMRT 靶区剂量高,周围正常组织受量小,不良反应轻,是一种治疗鼻咽癌的有效方法。治疗失败最主要的原因是远处转移,其发生率与颈淋巴结转密切相关。

     

    Abstract: Objective To analyse clinical efficacy of intensity modulated radiation therapy (IMRT) for primitive nasopharyngeal carcinoma (NPC). Methods From Jun 2006 to Aug 2008, 128 patients with NPCunderwent IMRT at our hospital. According to the 1992 Fuzhou Staging Classification, there were 2patients in stageⅠ,19 instageⅡ,58 instage Ⅲ and 49 in stage Ⅳa. The prescription dose was (70~74) Gy/30f to the nasopharynx gross tumor volume(GTVnx), (68~70)Gy/30f to positive neck lymph nodes (GTVnd), (60~64)Gy/30f to the first clinical target volume (CTV1) and (50~54)Gy/30f to the second clinical target volume (CTV2). Kaplan-Meier method was used to calculate the overall survival rate(OS),distant metastasis-free survival rate(DMFS),and local-regional control rates from the last day of therapy. Log-rank test was used to detect the difference between groups. Results The median follow-up interval was 12 month (6 ~24 months). The l-year and 2-year OS were 100% and 96.9%, DMFS were 92.2% and 88.3%, the local-regional control rates were 96.1% and 93.8%, respectively. Lymph node staging was the most important prognosis factor in affecting disease metastasis free survival rate ( P =0.04). The most serious acute toxicity was mucositis with GradeⅠto Ⅳof38.8%,48.4%,7.8% and0 respectively. The late toxicity was mostly salivary gland with GradeⅠ 67.2% and GradeⅡ 19.5%. Conclusion IMRT could improve the target volume dose and decrease the dose of surrounding tissue resulting in higher control rate and lower side effect. IMRT is a safe valid method.N(+) is significantly correlated with distant metastasis.

     

/

返回文章
返回